A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Inclusion criteria

• subjects voluntarily participated and signed a written informed consent form;
• age ≥18 years, male or female;
• ECOG PS 0-1;
• histopathologically diagnosed advanced malignant tumors;
• at least 1 measurable lesion according to RECIST v1.1 criteria or Lugano (2014) criteria;
• adequate organ function;

Exclusion criteria

• previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein;
• received anti-tumor therapy within 4 weeks prior to the first study treatment;
• history of autoimmune disease;
• history of other active malignancies within 3 years prior to the first treatment;
• history of serous cardiovascular events;